J&J pulls 200K Motrin bottles on plastic particles; Onyx investors sue over Amgen sale;

@FiercePharma: Onyx investors sue over $10.4B Amgen buyout, saying too favorable to Amgen. More from Bloomberg | Follow @FiercePharma

@EricPFierce: FDA approval of Abraxane for pancreatic cancer should extend lives for patients and sales for Celgene. ICYMI Friday | Follow @EricPFierce

@CarlyHFierce: The DoJ probes GSK for U.S. bribery violations in China, Reuters reports. FCPA probe of entire industry. Story | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) recalled 200,000 bottles of Motrin Infants Drops because they might have been contaminated with tiny particles of plastic. Report

> Onyx Pharmaceuticals ($ONXX) investors sued the company, claiming its planned $10.4 billion sale to Amgen ($AMGN) favors the buyer and that conflicts of interest "infected" the deal. Report

> Sagent Pharmaceuticals ($SGNT) announced a 4.44 million-share offering, comprising 3.38 million shares offered by the company and 1.06 million offered by selling shareholders. Report

> Former GlaxoSmithKline ($GSK) chairman Sir Richard Sykes now chairs a company, NetScientific, that plans to go public in the U.K. later this month. Report

> The Association of the British Pharmaceutical Industry's watchdog panel said Gedeon Richter breached its promotional code of practice. Report

Medical Device News

@FierceMedDev: From FierceDiagnostics: T2 jumps into pivotal trial for Candida assay. Article | Follow @FierceMedDev

@DamianFierce: After 22 years at the helm, AMRI's CEO is stepping down at year's end. Story from FierceCRO | Follow @DamianFierce

@MarkHFierce: J&J is sizing up buyers for its Ortho Clinical Diagnostics unit. Will it go for $5B? More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Capsugel picks up Bend Research with dispersion delivery tech. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Baxter finally closes $4B Gambro deal, eyes dialysis dominance. More

> CeQur's insulin pump draws $27M Series B. Article

> Sapheon nails down $19.8M for varicose vein treatment. Report

Biotech News

@FierceBiotech: New Industry Voices: Place your bets--A horse race emerges in the migraine space by Randall Schatzman, CEO of Alder. Article | Follow @FierceBiotech

@JohnCFierce: Another round of biotech IPOs is drawing near. ICYMI Friday | Follow @JohnCFierce

@Ry_McBride: GSK has given itself a dose (or doses) of online collaboration for its sales organization. More from InformationWeek | Follow @Ry_McBride

@EmilyMFierce: Potential Parkinson's-fighting compounds identified. FierceBiotech Research article | Follow @EmilyMFierce

> DRI Capital gains $1.45B in fresh firepower for drug royalty deals. Report

> Biogen fronts $100M to add Isis R&D pact on neurological diseases. Story

> Crowded field of PhIII COPD contenders will compete for blockbuster market. Article

CRO News

> Novella shuffles execs as Quintiles deal pends. Item

> AMRI chief stepping down at year's end. News

> Patheon posts Banner quarter on 30% sales surge. Article

> Covance teams with Indiana U. for early trials. Story

> Capsugel snaps up Bend with eye on oral formulations. More

Biotech IT News

> GlaxoSmithKline picks up online collaboration tools for medical staffers. Report

> Texas biotech software outfit trumpets open source tools. Item

> Genentech backs development of video game for kids with cancer. More

> In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Story

> Accelrys scoops up Bay Area software firm for $15.3M. Article

And Finally... A combination of two common antiviral drugs could be useful against the respiratory virus emerging in the Middle East. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.